NCT04901741: An ongoing trial by TME Pharma AG
This trial is ongoing. It must report results 3 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04901741 |
|---|---|
| Title | An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 31, 2026 |
| Completion date | March 31, 2028 |
| Required reporting date | March 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |